Amgen Hopes Kyprolis Label Expansion Will Give It A Leg Up In The Myeloma Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm believes addition of data from the ENDEAVOR trial, and new claims, will establish the proteasome inhibitor as a backbone of choice across lines of therapy.